Red bone marrow dose estimation using several internal dosimetry models for prospective dosimetry-oriented radioiodine therapy
- 105 Downloads
The aim of the present study was to review the available models developed for calculating red bone marrow dose in radioiodine therapy using clinical data. The study includes 18 patients (12 females and six males) with metastatic differentiated thyroid cancer. Radioiodine tracer of 73 ± 16 MBq 131I was orally administered, followed by blood sampling (2 ml) and whole-body scans (WBSs) done at several time points (2, 6, 24, 48, 72, and ≥ 96 h). Red bone marrow dose was estimated using the OLINDA/EXM 1.0, IDAC-Dose 2.1, and EANM models, the models developed by Shen and co-workers, Keizer and co-workers and Siegel and co-workers, and Traino and co-workers, as well as the single measurement model (SMM). The results were then compared to the standard reference model Revised Sgouros Model (RSM) reported by Wessels and co-workers. The mean dose deviations of the Traino, Siegel, Shen, Keizer, OLINDA/EXM, EANM, SMM, and IDAC-Dose 2.1 models from the RSM were − 17%, − 24%, 6%, − 29%, − 15%, 40%, 48%, and − 8%, respectively. The statistical analysis demonstrated no significant difference between the results obtained with the RSM and with those obtained with the Shen, Traino, OLINDA/EXM, and IDAC-Dose 2.1 models (t test; pvalue > 0.05). However, a significant difference was found between RSM doses and those obtained with the EANM, SMM, and Keizer models (t test; pvalue < 0.05). The correlation between red marrow dose from the SMM and EANM models was modest (R2 = 0.65), while the crossfire dose calculated with the OLINDA/EXM and IDAC-Dose 2.1 models were in good agreement with each other and with the reference model. The findings obtained indicate that most of the dosimetry models can be used for a reliable dosimetry, and the calculated total body doses can be considered as a reliable non-invasive option for a conservative activity planning. In addition, the excellent performance of the IDAC-Dose 2.1 model will be of particular importance for a practical and accurate dosimetry, with the advantages of allowing for the use of realistic advanced phantoms and updated dose fractions, and of providing information about the blood dose contribution to the red bone marrow.
KeywordsRed marrow Dosimetry models Radioiodine therapy IDAC-Dose 2.1
The authors would thank all the patients for their cooperation and patience.
This research did not receive any specific grant from any funding agency in the public, commercial, or not-for-profit sector.
Compliance with ethical standards
Conflict of interest
All authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.
All procedures performed in the current study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Istanbul University Cerrahpaşa Medical Faculty Clinical Research Ethics Committee approved this study (document number: 83045809/604/02-8877).
Informed consent was obtained from all the individual participants included in the study.
- Benua RS, Cicale NR, Sonenberg M, Rawson RW (1962) The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med 87:171–182Google Scholar
- Breitz B, Durham JS, Fisher DR, Weiden PL, DeNardo GL, Goodgold HM, Nelp WB (1995) Pharmacokinetics and normal organ dosimetry following intraperitoneal rhenium-186-labeled monoclonal antibody. J Nucl Med 36:754–761Google Scholar
- Chiesa C, Castellani MR, Vellani C, Orunesu E, Negri A, Azzeroni R, Botta F, Maccauro M, Aliberti G, Seregni E, Lassmann M, Bombardieri E (2009) Individualized dosimetry in the management of metastatic differentiated thyroid cancer. Q J Nucl Med Mol Imaging 53:546–561Google Scholar
- Council of the European Union (2013) Council Directive 2013/59/EURATOM. Off J Eur Union 56:216Google Scholar
- De Keizer B, Hoekstra A, Konijnenberg MW, Devos F, Lambert B, Van RP, Lips M, de Klerk JH (2004) Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer. J Nucl Med 45:1549–1554Google Scholar
- Hänscheid H, Canzi C, Eschner W, Flux G, Luster M, Strigari L, Lassmann M (2013) EANM dosimetry committee series on standard operational procedures for pretherapeutic dosimetry II. Dosimetry prior to radioiodine therapy of benign thyroid diseases. Eur J Nucl Med Mol Imaging 40:1126–1134CrossRefGoogle Scholar
- ICRP (2002) Basic anatomical and physiological data for use in radiological protection reference values. ICRP Publication 89. Annals of ICRP, vol 32, issue 3–4Google Scholar
- ICRP (2008) Nuclear Decay Data for Dosimetric Calculations. ICRP Publication 107. Annals of ICRP, vol 38, issue 3Google Scholar
- ICRP (2009) Adult Reference Computational Phantoms. ICRP Publication 110. Annals of ICRP, vol 39, issue 2Google Scholar
- ICRP (2016) The ICRP computational framework for internal dose assessment for reference adults: specific absorbed fractions. ICRP Publication 133 Ann ICRP 45(2):1–74Google Scholar
- Lassmann M, Hänscheid H, Chiesa C, Hindorf C, Flux G, Luster M (2008) EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging 35:1405–1412CrossRefGoogle Scholar
- Pearson TC, Guthrie DL, Simpson J, Chinn S, Barosi G, Ferrant A, Lewis SM, Najean Y (1995) Interpretation of measured red cell mass and plasma volume in adults: Expert Panel on Radionuclides of the International Council for Standardization in Haematology. Br J Haematol 89:748–756CrossRefGoogle Scholar
- Shen S, DeNardo GL, Sgouros G, O’Donnell RT, DeNardo SJ (1999) Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body. J Nucl Med 40:2102–2106Google Scholar
- Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, Robertson JS, Howell RW, Wessels BW, Fisher DR, Weber D, Brill B (1999) MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 40:37S– 61SGoogle Scholar
- Wessels BW, Bolch WE, Bouchet LG, Breitz HB, Denardo GL, Meredith RF, Stabin MG, Sgouros G (2004) Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison. J Nucl Med 45:1725–1733Google Scholar